In1-ghrelin剪接变体:肥胖与前列腺癌病理生理关联的关键要素
在PSA灰区(3–10 ng/mL)患者中,尿液In1-ghrelin水平与肥胖相关因素(BMI、糖尿病、血糖、胰岛素)及前列腺癌风险和侵袭性相关,并可为临床模型增加诊断价值。
要点
- 尿液In1-ghrelin与肥胖相关因素及前列腺癌风险、侵袭性相关。
- In1-ghrelin可为年龄、直肠指检、既往活检和PSA的临床模型增加诊断价值。
- 包含临床和代谢变量及In1-ghrelin的多变量模型诊断前列腺癌的AUC为0.740。
核心结论
- 尿液In1-ghrelin水平与肥胖相关因素及前列腺癌风险和侵袭性相关,可能成为新的非侵入性前列腺癌生物标志物。
研究设计与样本
- 在PSA灰区(3–10 ng/mL)且临床、代谢和病理特征明确的无前列腺癌(n=397)和有前列腺癌(n=213)患者队列中,用放射免疫分析法测定尿液In1-ghrelin水平。
主要发现
- 与前列腺癌风险相关的关键肥胖因素(BMI、糖尿病、血糖和胰岛素水平)与In1-ghrelin水平强相关。
- 前列腺癌患者的In1-ghrelin水平高于疑似前列腺癌但活检阴性的对照患者。
- 高In1-ghrelin水平与前列腺癌风险增加相关,并与前列腺癌侵袭性(如肿瘤分期、淋巴血管侵犯)相关。
- In1-ghrelin水平为包含年龄、可疑直肠指检、既往活检和PSA水平的临床模型增加了显著诊断价值。
- 包含临床和代谢变量(包括In1-ghrelin水平)的多变量模型诊断前列腺癌的AUC=0.740。
关键数值与推荐
- 尿液In1-ghrelin水平与BMI、糖尿病、血糖和胰岛素水平强相关。
- 包含临床和代谢变量及In1-ghrelin的多变量模型诊断前列腺癌的AUC=0.740。
临床怎么用
- 在PSA灰区患者中,可考虑检测尿液In1-ghrelin水平以辅助前列腺癌诊断和风险评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Recent studies emphasize the importance of considering the metabolic status to develop personalized medicine approaches. This is especially relevant in prostate cancer (PCa), wherein the diagnostic capability of prostate-specific antigen (PSA) dramatically drops when considering patients with PSA levels ranging from 3 to 10 ng/mL, the so-called grey zone. Hence, additional noninvasive diagnostic and/or prognostic PCa biomarkers are urgently needed, especially in the metabolic-status context. OBJECTIVE: To assess the potential relation of urine In1-ghrelin (a ghrelin-splicing variant) levels with metabolic-related/pathological conditions (eg, obesity, diabetes, body mass index, insulin and glucose levels) and to define its potential clinical value in PCa (diagnostic/prognostic capacity) and relationship with PCa risk in patients with PSA in the grey zone. METHODS: Urine In1-ghrelin levels were measured by radioimmunoassay in a clinically, metabolically, pathologically well-characterized cohort of patients without (n = 397) and with (n = 213) PCa with PSA in the grey zone. RESULTS: Key obesity-related factors associated with PCa risk (BMI, diabetes, glucose and insulin levels) were strongly correlated to In1-ghrelin levels. Importantly, In1-ghrelin levels were higher in PCa patients compared to control patients with suspect of PCa but negative biopsy). Moreover, high In1-ghrelin levels were associated with increased PCa risk and linked to PCa aggressiveness (eg, tumor stage, lymphovascular invasion). In1-ghrelin levels added significant diagnostic value to a clinical model consisting of age, suspicious digital rectal exam, previous biopsy, and PSA levels. Furthermore, a multivariate model consisting of clinical and metabolic variables, including In1-ghrelin levels, showed high specificity and sensitivity to diagnose PCa (area under the receiver operating characteristic curve = 0.740). CONCLUSIONS: Urine In1-ghrelin levels are associated with obesity-related factors and PCa risk and aggressiveness and could represent a novel and valuable noninvasive PCa biomarker, as well as a potential link in the pathophysiological relationship between obesity and PCa.
引用
- Jiménez-Vacas JM, Montero-Hidalgo AJ, Gómez-Gómez E, et al. In1-Ghrelin Splicing Variant as a Key Element in the Pathophysiological Association Between Obesity and Prostate Cancer. J Clin Endocrinol Metab. 2021. PMID: 34255835. doi:10.1210/clinem/dgab516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。